Remove 2013 Remove Clinical Trials Remove Patients Remove Treatment
article thumbnail

Canada: First patient in Quebec gets approval for magic mushroom therapy

Cannabis Law Report

When Thomas Hartle indulges in a session of psilocybin treatment, the end-of-life anxiety, distractions and noises associated with his terminal colon cancer go away. “Before the treatment, it’s like you’re sitting in your car. There must have been a lot of treatments done beforehand so the application is solid.”

Therapy 52
article thumbnail

Canada Opens Access for Psilocybin and MDMA Therapy

Cannabis Law Report

Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. 01.015 of the FDR before providing the new drug to a patient. Timeline of Medicinal Legalization in Canada. Pursuant to subsection C.08.010(1)

Therapy 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Realm of Caring Appoints Research Director to Oversee Groundbreaking Cannabis Data Registry and Medical Studies

Cannabis Law Report

This study represents a refreshing collaboration of scientists, clinicians, patients and advocates. It is our hope that this study may embolden clinicians and patients to effectively partner in considering these treatments.”. Based on these findings, he and study co-author Ryan Vandrey, Ph.D., About Realm of Caring.

Data 105
article thumbnail

Press Release: Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Cannabis Law Report

(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services.

article thumbnail

Best strains and terpenes for pain management

The Cannigma

Over 10% of US adults have suffered from some degree of daily pain for at least three months, so the need for improved treatment is clear. There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. 12 Pinene had the ability to meditate chemical responses to inflammation in rodent trials.

Terpenes 111
article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

article thumbnail

What is CBD? Everything you need to know

The Cannigma

Some healthcare professionals are already encouraged by what is known, much of it anecdotal accounts from patients in their practices. The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. Shutterstock).

CBD 122